Robert Whitfield MDAmerica's Breast Implant Illness Expert™

Breast Implant Illness: My Journey in Explaining & Testing! #shorts

19 Nov 2025 · 1 min

Watch on YouTube

1:25

Robert Whitfield MD briefly recounts his clinical experience with breast implant illness, tracing a first notable case in 2016 and his subsequent adoption of molecular testing protocols. He describes contacting MicroGenDX (Lubbock, Texas) about PCR testing and, since February 2019, sending explant samples from each side to MicroGenDX for analysis. He summarizes that their PCR panel targets DNA fragments from ~150 microorganisms (bacteria, fungi, molds, Mycobacterium) and notes iterative refinement of testing around late 2018–early 2019 and further clarification after the COVID-19 pandemic, with growing use of toxicity and genetic testing.

Questions this video answers

Since February 2019.

MicroGenDX (Lubbock, Texas).

About 150 different types (bacteria, fungi, molds, Mycobacterium).

Chapters

The last time I introduced the concept of breast implant illness and first case really was 2016, as I described in the previous video. That was very frustrating to me because I knew there was something, you know, wrong with the set of implants and led me to discuss PCR testing with a company out of Lubbock, Texas, MicroGenDX. And so since February of 2019, all of our samples from each side that we've done an explant from the operating room have went to Microgen DX for analysis. So PCR testing looks for DNA fragments. Ours looks for 150 different types of bacteria, fungi, Moldus fungi, Mycobacterium. Those have been, you know, in summary, so really, the first case around 2016, adjusting the PCR testing, late 18, early 19 post pandemic, really clarifying testing, using more and more testing for toxicity and genetics.